CD226 and neoplasm: Alongside natural cytotoxic activity against tumor cells, CAR-NK cells can also be activated through CAR-independent mechanisms, such as NCRs, NKG2D, costimulatory receptor DNAM-1 (CD226), certain activating KIRs, and through CD16-mediated ADCC [7,8].